Our team is diverse in background and expertise, but are all driven and motivated by one thing: serving patients. The team brings together decades of experience across many disciplines to accelerate the development and delivery of innovative gene therapies with the hopes of transforming patient lives.

 
Pavan Cheruvu, MD — Chief Executive Officer

Pavan Cheruvu, MD, has served as Axovant’s President and Chief Executive Officer since February 2018. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training as a clinical fellow in cardiovascular medicine at the University of California, San Francisco. Dr. Cheruvu previously worked as a management consultant at McKinsey & Company, where he focused on organizational and R&D strategy while serving a variety of clients, including large- and mid-cap biopharmaceutical firms. Dr. Cheruvu graduated summa cum laude from Duke University, obtained a master's degree from Oxford University as a Rhodes Scholar, and obtained his medical degree in a joint program between Harvard Medical School and the Massachusetts Institute of Technology. He also serves as a board observer at Arvelle Therapeutics. He currently lives with his wife and daughter in New York City.

Gavin Corcoran, MD — Chief R&D Officer

Gavin Corcoran, MD joined Axovant as Chief R&D Officer. In his career, he has overseen successful drug development across multiple therapeutic areas, including neurology and psychiatry, and was previously Chief Medical Officer of Allergan plc and Actavis. Dr. Corcoran was Executive Vice President for Global Medicines Development at Forest Laboratories prior to the acquisition of Forest Laboratories by Actavis. Dr. Corcoran also served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene, and as Chief Scientific Officer and head of R&D at Stiefel Laboratories. Earlier in his career he held leadership roles in clinical development and regulatory affairs at Amgen, Schering-Plough, and Bayer. He received his MB BCh from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.

Fraser Wright, PhD — Chief Technology Advisor

Fraser Wright, PhD, serves as Chief Technology Advisor, overseeing Axovant’s gene therapy initiatives. Dr. Wright is the Co-Founder and former Chief Technology Officer of Spark Therapeutics and has over 20 years of leadership experience in the development of novel vector-based biologic products. At Spark, he oversaw process development and clinical-stage manufacturing for LUXTURNA™. Prior to Spark, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at The Children’s Hospital of Philadelphia, where he directed clinical core staff in gene therapy investigational product development, manufacture, and quality control testing for ten first-in-human viral vector investigational products including LUXTURNA™ and Kymriah®. He was also previously the Director of Development and Clinical Manufacturing at Avigen. Dr. Wright is a former Research Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine, and he is the lead inventor on numerous issued patents during his time in that role. He received his BSc and PhD in biochemistry from the University of Toronto, where he was also an assistant professor of biochemistry and medicine.

David Nassif, JD — Chief Financial Officer

David Nassif, JD, serves as Chief Financial Officer at Axovant. He has more than 25 years of life sciences industry experience in executive financial management roles in development-stage, commercial-stage, public and private companies. Prior to joining Axovant, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in its acquisition by United Therapeutics in August 2018. From 2011 to 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen. Previously, he was Executive Vice President and Chief Financial Officer of Zogenix and held several key roles at Amphastar Pharmaceuticals and RealAge Inc. Earlier in his career, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc. He holds a B.S. in Finance and Management Information Systems with honors from the University of Virginia and a J.D. from the University of Virginia School of Law.

Parag Meswani, PharmD — Senior Vice President, Commercial Strategy and Operations

Parag Meswani, PharmD, joins Axovant as senior vice president of commercial strategy and operations. Dr. Meswani has over 17 years of experience in the biopharma industry, having served in various commercial and medical affairs leadership roles at Novartis, Pharmacia, Biogen, and most recently, Spark Therapeutics. At Spark, he served as head of U.S. marketing and diagnostics, leading the development and execution of the brand strategy for LUXTURNA™. Prior to Spark, Dr. Meswani held several corporate and franchise leadership roles at Biogen, including serving in the office of the CEO, commercial operations, the multiple sclerosis franchise and the U.S. hemophilia franchise. Dr. Meswani earned his M.B.A. from Columbia University and his Pharm.D. and B.S. from the Ernest Mario School of Pharmacy at Rutgers University.

Greg Stewart, PhD — Senior Vice President, Vector Delivery and Optimization

Greg Stewart, Ph.D., joins Axovant as senior vice president of vector delivery and optimization with responsibility for ongoing clinical refinement of Axovant’s gene therapy programs. Dr. Stewart has over 25 years of experience in drug development for neurological conditions from preclinical discovery to phase 2/3 clinical trials, most recently serving as chief scientific officer at Pairnomix. Prior to Pairnomix, he was vice president of vector delivery at Voyager Therapeutics, where he directed research to optimize targeted delivery of viral vectors to the brain and spinal cord for the treatment of neurodegenerative disease. Dr. Stewart has also held various scientific and development roles at Medtronic, Genzyme, ALZA and Roche and served as a fellow at the National Institute of Mental Health. He received his Ph.D. in neural sciences from Washington University in St. Louis and his B.S. in neuroscience from Texas Christian University.

Sean O’Bryan — Senior Vice President, Regulatory Affairs

Sean O’Bryan joins Axovant as vice president of regulatory affairs. Mr. O’Bryan has more than 25 years of regulatory experience including biologics, gene therapy and medical devices, most recently serving as vice president of regulatory affairs and quality assurance at Lysogene where he led all aspects of global regulatory affairs. Prior to Lysogene, he was senior director of regulatory affairs at Bluebird bio, where he served as regulatory strategist for CNS programs. Additionally, he built and led the CMC regulatory affairs group across all programs including CNS, hematology and oncology. Prior to Bluebird bio, he served as a global regulatory lead for the cell therapy and regenerative medicine division at Sanofi/Genzyme. Sean holds a B.S. in biology and analysis and policy from Boston University and is regulatory affairs professionals (RAPs) certified.

 
 
 
 
 
 
 

AXOVANT GENE THERAPIES

Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook

AXOVANT SCIENCES GMBH

Viaduktstrasse 8
4051 Basel
Switzerland